ADC Therapeutics SA (ADCT) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 93.9% versus a loss of 68.2%. Over five years, ADCT leads with a -94.2% price change compared with -95.7% for KRRO. ADC Therapeutics SA is the larger company by market cap ($180.0 million vs $167.2 million), about 1.1 times the size, while Korro Bio is growing revenue faster (+181.5% vs +14.9%).
ADC Therapeutics SA converts more of its revenue into profit, with a net margin of -175.3% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | KRRO |
|---|---|---|
| Share price | $1.28 | $12.18 |
| Market cap | $180.05M | $167.18M |
| 1-day change | -1.54% | -0.08% |
| YTD return | -63.74% | +52.06% |
| 1-year return | -68.16% | +93.95% |
| 5-year return | -94.23% | -95.67% |
| EPS (TTM) | $-0.46 | $-8.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.36M | $6.39M |
| Revenue growth (YoY) | +14.85% | +181.46% |
| Net income (latest FY) | $-142.62M | $-117.26M |
| Gross margin | 92.87% | — |
| Operating margin | -149.34% | -1906.37% |
| Net margin | -175.31% | -1834.48% |
| 52-week high | $4.98 | $17.35 |
| 52-week low | $0.78 | $5.20 |
| Distance from 52-week high | -74.30% | -29.81% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +160.16% | +76.52% |
| Average volume | 1.55M | 186.03K |
| Shares outstanding | 140.66M | 13.73M |
| Employees | 188 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed ADCT by 162.1 percentage points over the past year.
- ADC Therapeutics SA is more profitable, keeping -175.3 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
- Korro Bio grew revenue faster in its latest fiscal year (+181.46% vs +14.85%).
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ADCT vs KRRO FAQ
Which is bigger, ADC Therapeutics SA or Korro Bio?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $180.05M compared with $167.18M for Korro Bio (KRRO).
Which stock has performed better over the past year, ADCT or KRRO?
KRRO returned +93.95% over the past 12 months, compared with -68.16% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.